Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05725915
Other study ID # BJ-HDX-20220781
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2022
Est. completion date March 1, 2025

Study information

Verified date January 2023
Source Beijing Red Clove Public Welfare Development Center
Contact Shuhua Han, docter
Phone 13585148267
Email hanshuhua0922@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date March 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male and female, =18 years old; 2. Patients with a definite cytological or histopathological diagnosis of non-small cell lung cancer; 3. Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) NSCLC unable to receive radical surgery and/or radical radiotherapy (with or without concurrent chemotherapy) (AJCC cancer stage 8 clinical stage) 4. There is no known ALK gene translocation 5. For patients with EGFR-negative non-squamous cell carcinoma, or patients with EGFR-negative/unknown squamous cell carcinoma, it is required that they have not received systemic antitumor therapy for advanced NSCLC in the past (patients have received neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy or chemoradiotherapy for curing non-metastatic disease in the past, A disease-free interval of =6 months was required between the last chemotherapy and/or radiotherapy). 6. Patients with non-squamous cell carcinoma with EGFR-sensitive mutation and EGFR TKI progression could be enrolled if they met any of the following requirements: Progress in Treatment of 1/2 generation EGFR TKI, T790M-; EGFR TKI treatment progress of 1/2 generation, T790M+, after 3 generations of EGFR TKI treatment progress again; T790M status was not considered in patients who had progressed to the initial 3 generations of EGFR TKI therapy. 7. At least 1 measurable lesion according to RECIST 1.1 8. Receiving immune checkpoint inhibitor therapy for more than 2 cycles 9. ECOG PS 0-1 score 10. Be able to understand and abide by the requirements of the agreement, and voluntarily participate in the study. Exclusion Criteria: 1. Patients participating in other clinical studies; 2. Patients with serious lack of diagnosis and treatment data; 3. Patients could not understand the purpose of the study or disagreed with the requirements of the study; 4. A history of other tumors within 5 years; 5. Patients judged by the researchers as not suitable for inclusion in this study

Study Design


Locations

Country Name City State
China Shuhua Han Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Beijing Red Clove Public Welfare Development Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival(PFS)in days the time between the time a patient with tumor disease begins treatment and the time when disease progression is observed or death from any cause occurs. From date of enrollment until the date of first documented progression, assessed up to 2 years.
Secondary ctDNA in concentration The best predictive value of ctDNA concentration change threshold and the best collection time. The First treatment (month 1), the second treatment (month 2) and the time of progression (assessed up to 2 years)
See also
  Status Clinical Trial Phase
Recruiting NCT06003075 - Induction Chemo-Nivo in Unresectable Stage III NSCLC Phase 2
Enrolling by invitation NCT06293833 - Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan N/A
Recruiting NCT03705806 - Palliative Thoracic ImmunoRT
Not yet recruiting NCT06060964 - Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management Early Phase 1
Completed NCT04634630 - The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
Completed NCT03689634 - Move For Surgery - A Novel Preconditioning Program Phase 3
Recruiting NCT05537922 - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Completed NCT03902834 - Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery N/A
Active, not recruiting NCT03322072 - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating N/A
Completed NCT02995889 - FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer N/A
Recruiting NCT04237805 - A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients Phase 1/Phase 2
Terminated NCT05061940 - This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Recruiting NCT05860296 - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Phase 1/Phase 2
Suspended NCT02991651 - Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC Phase 1
Enrolling by invitation NCT04678440 - [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients Early Phase 1
Recruiting NCT04222335 - Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients N/A
Recruiting NCT04415320 - X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases Phase 2
Recruiting NCT02786589 - Plasmodium Immunotherapy for Lung Cancer Phase 1/Phase 2
Recruiting NCT05085028 - A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Phase 3
Completed NCT05956782 - Breathe Easier II: A Dyad-based Multiple Behavior Intervention N/A